These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 35054412)

  • 41. Visual impairment in neuromyelitis optica spectrum disorders (NMOSD).
    Wu Y; Zhong L; Geng J
    J Chem Neuroanat; 2019 Apr; 97():66-70. PubMed ID: 30716473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
    Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
    Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
    Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
    Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
    Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Asseyer S; Schmidt F; Chien C; Scheel M; Ruprecht K; Bellmann-Strobl J; Brandt AU; Paul F
    Mult Scler J Exp Transl Clin; 2018; 4(3):2055217318796684. PubMed ID: 30186620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort.
    Cross H; Sabiq F; Ackermans N; Mattar A; Au S; Woodhall M; Sun B; Devonshire V; Carruthers R; Sayao AL; Bhan V; Schabas A; Chan J; Fritzler M; Waters P; Traboulsee A
    Front Neurol; 2020; 11():525933. PubMed ID: 33510701
    [No Abstract]   [Full Text] [Related]  

  • 51. Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies.
    Paudel S; Nepal G; Guragain S; Shah S; Paudel BS; Ojha R; Rajbhandari R; Karn R; Gajurel BP; Paudel S
    Cureus; 2021 Mar; 13(3):e13968. PubMed ID: 33884229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A rare case of systemic lupus erythematosus-associated neuromyelitis optica spectrum disorder with cystic lesions and dual seropositivity for anti-AQP4 and anti-MOG antibodies.
    Al Jassem O; Rifi R; Kheir K; Masri A; Eid H
    Clin Case Rep; 2024 Sep; 12(9):e9063. PubMed ID: 39219777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
    Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
    Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.
    Rosenthal JF; Hoffman BM; Tyor WR
    J Investig Med; 2020 Feb; 68(2):321-330. PubMed ID: 31582425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease.
    Dinoto A; Sechi E; Flanagan EP; Ferrari S; Solla P; Mariotto S; Chen JJ
    Front Neurol; 2022; 13():866824. PubMed ID: 35401423
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.